Clinical Trial for Assessment of Anti-SARS-CoV-2 Serum for Early Treatment of COVID-19 Cases

Study Overview
=================
Brief Summary
-----------------
Phase I/II Randomized Clinical Trial to evaluate the safety, pharmacokinetic and efficacy of Anti-SARS-CoV-2 hyperimmune serum. The study will include patients at early stage of COVID-19 with increased risk for severe disease due to underlying medical conditions to determine the utility of an equine heterologous serum anti-SARS-CoV-2 to avoid progression to a severe COVID-19

Detailed Description
-----------------
Phase I/II Clinical Trial, randomized, multicentric, on three stages (A, B and C) to evaluate the safety, pharmacokinetic and efficacy of Anti-SARS-CoV-2 serum and dose escalation. The study will be in three stages: Stage A: 30 kidney transplanted participants (very high risk), where 15 will received 1 vial (5 mL) and 15 will received 2 vials (10 mL) of serum; Stage B: 30 immunocompetent participants with at least 2 risk factors for severe disease (high risk) who will receive the dose selected by stage A; Stage C: 558 participants, of very high risk and high risk, compared with placebo in allocation 2:1 (endpoint-driven design) Allocation type Open study without allocation of randomization on Stages A and B Randomized allocation with placebo comparator in Stage C. Recruitment Status: On planning Date of 1st recruitment Expected: April 2021 Target sample siz 618 (30/30/538) participants .

Official Title
-----------------
Phase I/II Clinical Trial for Dose Escalation and Safety Assessment and Clinical Response of Anti-SARS-CoV-2 Serum Produced by Instituto Butantan

Conditions
-----------------
Immunosuppression, Cancer, COVID-19, Other Complication of Kidney Transplant, Chemotherapy, Renal Disease, Diabetes Mellitus, Cardiovascular Diseases, Chronic Obstructive Pulmonary Disease

Intervention / Treatment
-----------------
* Biological: AntiSARS-CoV-2 Serum
* Other: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adults 18 years of age or older; Diagnosis of SARS-CoV-2 infection confirmed by RT-PCR or antigen test no more than 5 days ago; Onset of clinical signs and symptoms of COVID-19 no more than 5 days manifested as: Presenting sudden onset of anosmia and/or ageusia without any other reasonable explanation and/or; Thoracic image by radiography, tomography or ultrasonography compatible with acute clinical symptoms findings of COVID-19 and/or; Acute onset of cough accompanied by fever and/or Acute onset of three or more of the following symptoms: fever, cough, fatigue or general weakness, headache, myalgia, sore throat, runny nose, dyspnea, anorexia or nausea or vomit, diarrhea and mental status change. Oxygen saturation by pulse oximetry ≥92% Agree to periodic contacts by phone, electronic means and home visits; Demonstrate intention to participate in the study, documented by Informed Consent Form signature on the part of the participant. For the very high risk group: Being on continuous drug immunosuppressant more than two weeks due to a basic medical condition (e.g. transplant or cancer); For the high risk group: To present at least two risk factors for developing serious COVID-19 (Over 60 years of age; diabetes mellitus; chronic obstructive pulmonary disease; kidney disease; cardiovascular diseases and body mass index ≥ 35). Exclusion Criteria: Presenting COVID-9 in need of oxygen therapy on the moment of study inclusion, in other words, score 5 or higher in WHO COVID-19 progression scale; Behavioral, cognitive or psychiatric disease that, in principal investigator opinion or his/her medical representative, affect the participant capacity in understanding and collaborating with study protocol requirements; Any use considered alcohol or drugs abuse in the last 12 months prior to study inclusion that caused medical, professional or family problems, as indicated by clinical history; Severe allergic reaction history or anaphylaxis to heterologous serum or product components of the study; To have received heterologous serum or convalescent plasma in the last three months before of study inclusion, or planned administration of hemoderivatives or immunoglobulin on the next 28 days of study inclusion; The participant is a team member who is conducting the study or is in a dependent relationship with one of the study team members. Dependency relationships include close relatives (in other words, sons, partner/spouse, brothers, parents), as well as Researcher staff or staff from the location conducting the study; Any other condition that, in the principal investigator opinion or his/her medical representative, could threaten the safety or rights of a potential participant or which prevents him from fulfilling with this protocol. For female: Pregnancy (confirmed by positive β-hCG test), breastfeeding and/or expressing an intention to have sexual practices with reproductive potential without using a contraceptive method within four weeks of the product administration; For stages A and B: Previous immunization with vaccine against COVID-19

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: Phase I/II Clinical Trial, randomized, multicentric, on three stages (A, B and C) to evaluate the safety, pharmacokinetic and efficacy of Anti-SARS-CoV-2 serum and dose escalation. The study will be in three stages: Stage A: 30 kidney transplanted participants (very high risk), where 15 will received 1 vial (5 mL) and 15 will received 2 vials (10 mL) of serum; Stage B: 30 immunocompetent participants with at least 2 risk factors for severe disease (high risk) who will receive the dose selected by stage A; Stage C: 558 participants, of very high risk and high risk, compared with placebo in allocation 2:1.
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Experimental product group (Stage A)<br>Anti-SARS-CoV-2 Serum Dose: 5 mL/dose or 10 mL/dose Administration Route: Intravenous | Biological: AntiSARS-CoV-2 Serum<br>* Stage A: 30 kidney transplanted participants (very high risk), where 15 will received 1 vial (5 mL) and 15 will received 2 vials (10 mL) of serum; Stage B: 30 immunocompetent participants with at least 2 risk factors for severe disease (high risk) who will receive the dose selected by stage A; Stage C: 558 participants, of very high risk and high risk, compared with placebo in allocation 2:1.<br>|
| Placebo Comparator: Placebo group (Stage C)<br>Saline solution Administration Route: Intravenous | Other: Placebo<br>* Saline solution Administration Route: Intravenous<br>|
| Experimental: Experimental product group (Stage B)<br>Anti-SARS-CoV-2 Serum Dose: 5 mL/dose or 10 mL/dose Administration Route: Intravenous | Biological: AntiSARS-CoV-2 Serum<br>* Stage A: 30 kidney transplanted participants (very high risk), where 15 will received 1 vial (5 mL) and 15 will received 2 vials (10 mL) of serum; Stage B: 30 immunocompetent participants with at least 2 risk factors for severe disease (high risk) who will receive the dose selected by stage A; Stage C: 558 participants, of very high risk and high risk, compared with placebo in allocation 2:1.<br>|
| Experimental: Experimental product group (Stage C)<br>Anti-SARS-CoV-2 Serum Dose: 5 mL/dose or 10 mL/dose Administration Route: Intravenous | Biological: AntiSARS-CoV-2 Serum<br>* Stage A: 30 kidney transplanted participants (very high risk), where 15 will received 1 vial (5 mL) and 15 will received 2 vials (10 mL) of serum; Stage B: 30 immunocompetent participants with at least 2 risk factors for severe disease (high risk) who will receive the dose selected by stage A; Stage C: 558 participants, of very high risk and high risk, compared with placebo in allocation 2:1.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Frequency of local and systemic adverse events | Frequency of local and systemic adverse events, solicited and unsolicited, during the infusion and within 12 hours after administration of the heterologous serum | 12 hours after product administration | 
| Anti-SARS-CoV-2 serum average life | Anti-SARS-CoV-2 serum average life measured by equine antibodies levels | 28 days after product administration | 
| Proportion of patients with change in COVID-19 disease progression profile after administration of anti-SARS-CoV-2 serum | Proportion of patients with change in COVID-19 disease progression profile after administration of anti-SARS-CoV-2 serum, based on the WHO clinical progression scale (not progression to severe disease requiring mechanical ventilation or death - Score 7 or larger) | 14 days after product administration | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Frequency of local and systemic adverse events | Frequency of local and systemic adverse events, solicited and unsolicited, up to 28 days of serum heterologous administration | 28 days after product administration | 
| Frequency of severe adverse events | Frequency of severe adverse events and of the special interest up to 28 days after administration of serum heterologous | 28 days after product administration | 
| Clinical response | Clinical response according serum anti-SARS-CoV-2 dosage | 14 days after product administration | 
| Symptoms duration | Symptoms duration associated to COVID-19 | 28 days after product administration | 
| Hospitalization time in Intensive Care Unit | Hospitalization time in Intensive Care Unit related to COVID-19 | 28 days after product administration | 
| Deaths | Frequency of deaths by COVID-19 | 28 days after product administration | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Anti-SARS-CoV-2 serum, safety, pharmacokinetic, efficacy